Absci Corp is trading 5.1% up at $7.55 following bullish analyst commentary regarding its AI-native biologics platform and growing investor interest in AI drug discovery.
- Leerink recently highlighted the company's pipeline value, contributing to a series of price target hikes that have bolstered investor confidence.
- The stock's upward move is further supported by broader market strength and a risk-on sentiment across innovative biotechnology names.